Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study
American Journal of Transplantation · 2025-06 · 25 (6) · 1285-1295
DOI: 10.1016/j.ajt.2025.01.005 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift American Journal of Transplantation, 2025-06. Verfasst von Suk-Chan Jang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Liver Transplantation, Everolimus, Immunosuppressive Agents, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Center, Korea Ministry of Health and Welfare.
Abstract (Originalsprache)
The potential of everolimus (EVR) in reducing hepatocellular carcinoma (HCC) among recipients following liver transplantation has been reported. This nationwide population-based quasi-cohort study investigated whether combining EVR with calcineurin inhibitor therapy affects the risk of HCC and extrahepatic cancers compared to a time duration-matched cohort of recipients not receiving EVR. Using data covering the entire population from Korea, liver transplant recipients who had initiated immunosuppressants between June 2015 and February 2020 were included, and divided into 2 groups: the EVR combination and noncombination groups. We calculated adjusted hazard ratios (aHRs) and absolute risk reduction for the risk of HCC and extrahepatic cancer with EVR combination therapy using a Cox regression model. A time duration-matched retrospective cohort of 932 recipients in both of the groups was identified. The EVR combination group showed a lower risk of HCC (aHR, 0.53; 95% confidence interval, 0.30-0.94) and extrahepatic cancers (aHR, 0.30; 95% confidence interval, 0.14-0.63) compared to the noncombination group. The absolute risk reduction was 0.004 for HCC and 0.012 for extrahepatic cancer. The findings suggest that adding EVR to calcineurin inhibitor therapy reduces cancer risk in liver transplant recipients, highlighting the importance of considering cancer risk when choosing immunosuppressive therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
- Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- College of Pharmacy, Sahmyook University, Seoul, Republic of Korea. Electronic address: kimhye-lin@syu.ac.kr.
- School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea. Electronic address: ekyung@skku.edu.
Förderung
- National Cancer Center
- Korea Ministry of Health and Welfare
Zitieren
APA
Jang, S. C., Kim, G. A., Lim, Y. S., Kim, H. L., & Lee, E. K. (2025). Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study. American Journal of Transplantation, 25(6), 1285-1295. https://doi.org/10.1016/j.ajt.2025.01.005
Vancouver
Jang SC, Kim GA, Lim YS, Kim HL, Lee EK. Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study. American Journal of Transplantation. 2025;25(6):1285-1295. doi:10.1016/j.ajt.2025.01.005
BibTeX
@article{Jang2025,
author = {Jang, Suk-Chan and Kim, Gi-Ae and Lim, Young-Suk and Kim, Hye-Lin and Lee, Eui-Kyung},
title = {Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study},
journal = {American Journal of Transplantation},
year = {2025},
volume = {25},
number = {6},
pages = {1285--1295},
doi = {10.1016/j.ajt.2025.01.005}
}
EUVIMED